The trial of Fintepla in Dravet Syndrome and LGS was run by researchers at the Brno Epilepsy Centre in Czechia.

Fintepla (fenfluramine) is a prescription drug used to treat seizures from certain epilepsy conditions. Fintepla can cause side effects that range from mild to serious. Examples include diarrhea and ...

Fintepla (fenfluramine) is an oral solution used to treat seizures from certain epilepsy conditions. It’s typically taken twice daily. Specific doses are based on body weight and calculated by your ...

How Does Fintepla Work for Seizures? Seizures are caused by sudden electrical activity changes in the brain. These changes are temporary but result in changes in movement, behavior, sensation, or ...

FINTEPLA® has demonstrated efficacy in the most difficult-to-treat seizure types,1,2 including drop seizures, which cause a person to suddenly lose muscle tone, become limp, and fall to the ground, ...

ATLANTA, June 24, 2024 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced that Epilepsia published findings from a comprehensive scoping review examining the efficacy of ...

As UCB works to secure U.S. approval for its promising plaque psoriasis prospect bimekizumab, the company has landed an FDA nod in a rare disease where it will challenge Jazz Pharmaceuticals. Fintepla ...

UCB plans to file for regulatory approval of Fintepla to treat a third epileptic condition “as soon as possible,” the company said, as it reported results of a phase 3 trial in patients with the ultra ...

UCB’s Fintepla (fenfluramine) has been associated with a nearly 50% reduction in countable motor seizure frequency (CMSF) in adult and paediatric patients with cyclin-dependent kinase-like 5 (CDKL5) ...

EMERYVILLE, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Zogenix, a global biopharmaceutical company specializing in rare disease therapies, announced that it has submitted a New Drug Application (J-NDA) ...

Oral solution approved to treat seizures associated with Dravet syndrome The European Commission (EC) has approved Zogenix’s Fintepla (fenfluramine) for the treatment of seizures associated with ...

FINTEPLA is approved by the U.S. Food and Drug Administration (FDA) for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients two years of age and older 1 ...